William Blair initiated coverage on Natera Inc. NTRA, highlighting the company's strong positioning in the emerging minimal ...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today highlighted Allogene Therapeutics ...
Natera (NTRA) has moved into focus after a favorable patent ruling against ArcherDx and Invitae, royalty income tied to MRD products, broad uptake of its Signatera test, and recent progress toward ...
Investor's Business Daily on MSN
IBD rating upgrades: Natera shows improved relative price strength
A Relative Strength Rating upgrade for Natera shows improving technical performance. Will it continue?
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will present new data at the 2025 International Association for the Study of Lung Cancer ...
Natera, Inc. (NASDAQ: NTRA) a global leader in cell-free DNA and precision medicine, today announced that 20 abstracts, including two oral presentations, featuring data generated using its ...
Natera ( (NTRA)) has provided an update. Natera’s Board of Directors has expanded from ten to eleven members and appointed Eric Rubin as an independent Class I director, effective March 26, 2026, with ...
Natera's robust financial performance, driven by strong growth in its Women’s Health and Oncology segments, justifies its recent stock price surge and positive outlook. The company’s strategic ...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication in npj Precision Oncology of the validation study for its Latitude tissue-free ...
Guardant Health has filed a lawsuit against its competitor, Natera, alleging the misappropriation of trade secrets related to cancer-detection blood tests, according to court documents. According to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results